,63 Importantly, therapies targeting IL-6 and IL6R are approved for several conditions including rheumatoid arthritis, cytokine release syndrome, giant cell arteritis, and multicentric Castleman disease.64 This evidence concerns the gene IL6R and temporal arteritis.